Published in Gene Ther on March 26, 2015
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. Vaccines (Basel) (2015) 0.77
The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75
A C-terminal signal prevents secretion of luminal ER proteins. Cell (1987) 14.83
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer (2010) 4.99
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Human growth hormone: complementary DNA cloning and expression in bacteria. Science (1979) 3.67
Expanding roles for CD4⁺ T cells in immunity to viruses. Nat Rev Immunol (2012) 2.94
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science (2000) 2.70
DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol (2006) 1.79
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix. J Clin Pathol (1994) 1.70
Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis (1997) 1.57
A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene (2003) 1.42
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
Viral integration and fragile sites in human papillomavirus-immortalized human keratinocyte cell lines. Genes Chromosomes Cancer (1992) 1.12
Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res (2001) 1.06
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol (2007) 0.96
Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther (2004) 0.91
An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine (2006) 0.90
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther (2005) 0.89
A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8(+) T cell responses. Proc Natl Acad Sci U S A (2007) 0.87
Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther (2002) 0.86
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther (2007) 0.85
Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Int J Cancer (2011) 0.82
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm (2010) 0.79
Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther (2012) 0.79
The effect of helper epitopes and cellular localization of an antigen on the outcome of gene gun DNA immunization. Gene Ther (2014) 0.78